Topical gel could be a breakthrough in cancer wounds
Vyome Therapeutics has shared interim results from its Phase II proof of concept study of VT-1953 topical gel in people with malignant fungating wounds (MFW). VT-1953, which exerts an immuno-anti-inflammatory effect by targeting TLR-MD2 and DNA gyrase, met its primary endpoint in this interim analysis, with patients… Read More